Expression of programmed death ligand 1 in liver cancer and its clinical significance
10.3760/cma.j.issn.1006-9801.2019.09.001
- VernacularTitle: 程序性死亡受体配体1在肝癌中的表达及其临床意义
- Author:
Yuan ZHANG
1
;
Feng ZHANG
;
Lixin SUN
;
Zhihua YANG
;
Yuliang RAN
;
Lichao SUN
Author Information
1. State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Programmed death ligand 1;
Immunohistochemistry
- From:
Cancer Research and Clinic
2019;31(9):577-580
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of programmed death ligand 1 (PD-L1) in liver cancer tissues and its clinical significance.
Methods:The expression levels of PD-L1 in 110 liver cancer tissues, including 95 cases of hepatocellular carcinoma and 15 cases of cholangiocarcinoma were detected by using immunohistochemical staining method, and the relationship between PD-L1 expression and the clinicopathological characteristics of patients with hepatocellular carcinoma was analyzed.
Results:Immunohistochemistry results showed that the positive rate of PD-L1 in liver cancer tissues was 69.1% (76/110), and the positive rate of membrane and cytoplasm was 46.4% (51/110) and 22.7% (25/110), respectively. The positive rate of PD-L1 expression in hepatocellular carcinoma was higher than that in cholangiocarcinoma [78.9% (75/95) vs. 6.7% (1/15)], and the difference was statistically significant (χ 2 = 31.693, P < 0.01). The positive expression of PD-L1 was closely associated with the depth of invasion and TNM stage of hepatocellular carcinoma (both χ2 = 4.629, both P = 0.031), but there was no relationship with the patients'age, gender and pathological grade (all P > 0.05). Further analysis showed that protein expression localization of PD-L1 was closely related to the pathological grade in hepatocellular carcinoma (P = 0.013).
Conclusion:The positive expression of PD-L1 in hepatocellular carcinoma is closely associated with depth of invasion and TNM stage, which provides a theoretical basis for the immunotherapy of liver cancer targeting PD-L1.
